Design and evaluation of EphrinA1 mutants with cerebral protective effect

DSpace/Manakin Repository

Design and evaluation of EphrinA1 mutants with cerebral protective effect

Citable link to this page

 

 
Title: Design and evaluation of EphrinA1 mutants with cerebral protective effect
Author: Zhu, Yuanjun; Gao, Yuanqing; Zheng, Danping; Shui, Mengyang; Yu, Kuai; liu, Xiaoyan; Lin, Yuan; Su, Li; Yang, Wenxing; Wang, Yinye

Note: Order does not necessarily reflect citation order of authors.

Citation: Zhu, Yuanjun, Yuanqing Gao, Danping Zheng, Mengyang Shui, Kuai Yu, Xiaoyan liu, Yuan Lin, Li Su, Wenxing Yang, and Yinye Wang. 2017. “Design and evaluation of EphrinA1 mutants with cerebral protective effect.” Scientific Reports 7 (1): 1881. doi:10.1038/s41598-017-02091-7. http://dx.doi.org/10.1038/s41598-017-02091-7.
Full Text & Related Files:
Abstract: The activation of EphA2 receptor by its natural ligand EphrinA1 causes blood brain barrier dysfunction, and inactivation of EphA2 reduces BBB damage in ischemic stroke. Thus, EphA2 targeted antagonists may serve as neuroprotective agents. We engineered four mutants of EphrinA1, EM1, EM2, EM3 and EM4, respectively. The computational analysis showed that these four mutants were capable of interacting with EphA2. Their potential neuroprotective effects were examined in mouse focal ischemia/reperfusion (I/R) model. EM2 exhibited strong neuroprotective effects, including reduced brain infarct volume, neuronal apoptosis, cerebral edema, and improved neurological scores. The EM2-mediated protection was associated with a comparative decrease in BBB leakage, inflammatory infiltration, and higher expression levels of tight junction proteins, such as zonula occludens-1 and Occludin. I/R-induced high expression of Rho-associated protein kinase 2 (ROCK2) was down-regulated after EM2 treatment. Moreover, EM2 reduced agonist doxazosin-induced EphA2 phosphorylation and cells rounding in PC3 cells, indicating EphA2-antagonizing activity of EM2. These finding provided evidences of the neuroprotection of EphA2 antagonist and a novel approach for ischemic stroke treatment. These results also suggested that a receptor agonist can be switched to an antagonist by substituting one or more relevant residues.
Published Version: doi:10.1038/s41598-017-02091-7
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432519/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029983
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters